MajorNSAID, acetic acid derivative, COX-1/COX-2 inhibitor×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
Tacrolimus can impair renal function on its own. Drugs with known nephrotoxic or neurotoxic effects, including non-steroidal anti-inflammatory drugs (NSAIDs), may potentiate these effects of tacrolimus (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Aceclofenac is an NSAID. Its SmPC states that NSAIDs given with tacrolimus are thought to increase the risk of nephrotoxicity because less prostacyclin is formed in the kidney (aceclofenac SmPC, AEMPS). NSAIDs can reduce prostaglandin formation in a dose-dependent way and lead to renal failure (aceclofenac SmPC, AEMPS). Tacrolimus is more than 98.8% bound to plasma proteins and aceclofenac more than 99%. The tacrolimus SmPC asks prescribers to consider possible interactions with other highly protein-bound drugs, including NSAIDs (AEMPS).
Symptoms
Tacrolimus very commonly impairs renal function and causes hyperkalaemia. Common reactions include oliguria and renal failure, including acute renal failure (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acute renal impairment from tacrolimus toxicity can show as high serum creatinine, hyperkalaemia, reduced urea excretion and hyperuricaemia, and is usually reversible (tacrolimus label, US Food and Drug Administration, FDA). The aceclofenac SmPC lists raised blood urea and creatinine, nephrotic syndrome, renal failure, oedema and hyperkalaemia among its adverse reactions. The effects on renal function reverse when aceclofenac is stopped (aceclofenac SmPC, AEMPS).
Management
The combination is not contraindicated. The tacrolimus summary of product characteristics (SmPC) recommends avoiding tacrolimus with drugs that have known nephrotoxic effects and explicitly lists non-steroidal anti-inflammatory drugs (NSAIDs) among them. Aceclofenac belongs to this class (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, closely monitor tacrolimus trough blood levels, renal function and other adverse effects. Adjust the tacrolimus dose if needed, and consider reducing it if nephrotoxicity occurs (AEMPS). Monitor renal function closely while aceclofenac and tacrolimus are taken together (aceclofenac SmPC, AEMPS). The US tacrolimus label says to monitor renal function and tacrolimus blood levels when tacrolimus is combined with other known nephrotoxic drugs. During concurrent use, adjust the dose of tacrolimus, the other drug or both (tacrolimus label, US Food and Drug Administration, FDA). Aceclofenac is contraindicated in severe renal impairment. In mild or moderate renal impairment, the SmPC advises the lowest effective dose and regular checks of renal function (aceclofenac SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Prograf (tacrolimus) prescribing information (2025)– Astellas Pharma US. PROGRAF (tacrolimus) capsules, injection, granules. Prescribing information, DailyMed setid 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Aceclofenaco, Airtal 100 mg (nº registro 59024), secciones 4.3, 4.4 y 4.5 (2023)– AEMPS, CIMA, nº registro 59024 (Airtal 100 mg comprimidos recubiertos con película, Almirall), revisión 02/2023, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 5.2